Administration of intekleukin-1 (IL-1) into the cerebral ventricles produces marked physiological and behavioral effects. However, the precise locations within the central nervous system that mediate these effects have not been determined. Previous studies indicated that IL-1 induces neurophysiological, neurochemical and neuroendocrine changes within the hypothalamic paraventricular nucleus (PVN). These findings suggest that the PVN is also involved in mediating the behavioral effects of IL-1. This hypothesis was tested by examining the effects of administration of IL-1Β (10 or 50 ng/rat) or saline, either intracerebroventricularly or into the PVN, on fever and several behavioral parameters. IL-1Β, administered into both locations, induced a comparable suppression of motor activity, reduction in food and saccharine consumption, and loss of body weight. The febrile response to IL-1Β, assessed by a biotelemetric system, was significantly greater following administration into the PVN than into the lateral ventricle. Additionally, IL-1 administration into adjacent thalamic locations had no febrile or behavioral effects. These findings suggest that the PVN may be one of the brain structures involved in mediating the response to IL-1.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.